首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

2039915

乳癌：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

Breast Cancer - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035

出版日期: 2025年11月29日 | 出版商:

Thelansis Knowledge Partners | 英文 155 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

市場概覽

法國乳癌市場預計將從 2025 年的 21 億美元成長到 2035 年的 48 億美元。
市場成長是由標靶治療、生物製藥和抗體偶聯藥物（ADC）的普及所推動的。
未來的成長取決於 HER2 低表達、HR 陽性和三陰性乳癌治療的創新。

乳癌概述

乳癌是全球女性最常見的惡性腫瘤，可分為荷爾蒙受體陽性（HR+）、HER2陽性和三陰性（TNBC）三種亞型。早期乳癌的治療方法包括手術、放射治療、亞型特異性的輔助性全身治療。在晚期病例中，精準醫療已徹底改變了治療模式。對於HR+型乳癌，內分泌治療合併CDK4/6抑制劑是標準治療方案。對於HER2+和HER2低表達型乳癌，HER2標靶治療和抗體偶聯藥物（ADC）（如曲妥珠單抗、T-DM1）發揮核心作用。對於TNBC，沙妥珠單抗和免疫療法（如PD-L1陽性TNBC患者可使用Pembrolizumab）提供了新的治療選擇。化療仍然十分重要，尤其是在進行性，但基因組檢測（例如BRCA突變）指南PARP抑制劑的使用。預防和早期發現篩檢仍然是全球策略的基礎。

主要亮點

在德國，根據存活率調整後，預計乳癌病例數將從 2025 年的 3,692,865 例增加到 2035 年的 3,949,454 例。
儘管乳癌的存活率有所提高，但它仍然是女性中最常見的癌症，也是該療法的適應症。
精準腫瘤學和 CDK4/6標靶治療的日益普及正在重塑治療標準。
轉移性乳癌和難治性乳癌亞型仍有未被滿足的需求。

格式化和更新訊息

詳細報告（PDF）
市場預測模型（基於微軟Excel）
流行病學數據（MS Excel，互動式工具）
高階主管洞察（PPT簡報）
其他功能：定期更新、自訂和顧問支援。
根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
未來十年市場收入和病患佔有率的預測是多少？
哪些因素對市場趨勢影響最大？
受訪專家對目前和新興的治療方法有何看法？
哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
為確保藥物核准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

G8
- 美國
- EU5
  - 法國
  - 德國
  - 義大利
  - 西班牙
  - 英國
- 日本
- 中國

大公司

Pfizer
Merck Sharp &Dohme LLC
Boundless Bio, Inc.
Sichuan Baili Pharmaceutical Co., Ltd.
MedSIR
ExpreS2ion Biotechnologies
Stemline Therapeutics, Inc.
Genentech, Inc.
Cellectar Biosciences, Inc.
SURGE Therapeutics
Eli Lilly and Company
Celcuity Inc
Arvinas Estrogen Receptor, Inc.
Tolmar Inc.
Jazz Pharmaceuticals
Hoffmann-La Roche
Regor Pharmaceuticals Inc.
AstraZeneca
Eisai Inc.
SCRI Development Innovations, LLC
Beijing Wehand-Bio Pharmaceutical Co., Ltd.
Shandong Suncadia Medicine Co., Ltd.
InventisBio Co., Ltd
Daiichi Sankyo
TransThera Sciences（Nanjing）, Inc.
Atridia Pty Ltd.
Novartis Pharmaceuticals
Olema Pharmaceuticals, Inc.
Greenwich LifeSciences, Inc.
Incyclix Bio

Thelansis's "Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Breast Cancer Overview

Breast cancer is the most common malignancy in women worldwide, classified into hormone receptor-positive (HR+), HER2-positive, and triple-negative (TNBC) subtypes. Early-stage disease is managed with surgery, radiation, and subtype-specific adjuvant systemic therapy. In advanced disease, precision medicine has transformed care: endocrine therapy plus CDK4/6 inhibitors is standard for HR+ disease; HER2-targeted therapies and ADCs (trastuzumab deruxtecan, T-DM1) are central for HER2+ and HER2-low tumors; and sacituzumab govitecan and immunotherapy (pembrolizumab for PD-L1+ TNBC) provide new options in TNBC. Chemotherapy remains important, especially in aggressive disease, while genomic testing (e.g., BRCA mutations) guides PARP inhibitor use. Prevention and early detection through screening continue to underpin global strategies.

Key Highlights

In Germany, survival-adjusted prevalent Breast Cancer cases are projected to increase from 3,692,865 in 2025 to 3,949,454 by 2035.
Breast cancer remains the most prevalent cancer indication among women with improving survival outcomes.
Increasing use of precision oncology and CDK4/6-targeted therapies is reshaping treatment standards.
Persistent unmet need exists in metastatic and treatment-resistant breast cancer subtypes.

Market Overview

The France Breast Cancer market is projected to grow from USD 2.1 billion in 2025 to USD 4.8 billion by 2035.
Market growth is driven by strong uptake of targeted therapies, biologics, and ADCs.
Future growth will depend on innovation in HER2-low, HR-positive, and triple-negative breast cancer therapies.

Insights driven by robust research, including:

In-depth interviews with leading KOLs and payers
Physician surveys
RWE analysis for claims and EHR datasets
Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

Detailed Report (PDF)
Market Forecast Model (MS Excel-based automated dashboard)
Epidemiology (MS Excel; interactive tool)
Executive Insights (PowerPoint presentation)
Others: regular updates, customizations, consultant support
As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

10-year market forecast (2025-2035)
Bottom-up patient-based market forecasts validated through the top-down sales methodology
Covers clinically and commercially-relevant patient populations/ line of therapies
Annualized drug-level sales and patient share projections
Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
Detailed methodology/sources & assumptions
Graphical and tabular outputs
Users can customize the model based on requirements

Key business questions answered:

How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
What is the 10-year market outlook for sales and patient share?
Which events will have the greatest impact on the market's trajectory?
What insights do interviewed experts provide on current and emerging treatments?
Which pipeline products show the most promise, and what is their potential for launch and future positioning?
What are the key unmet needs and KOL expectations for target profiles?
What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

G8
- United States
- EU5
  - France
  - Germany
  - Italy
  - Spain
  - U.K.
- Japan
- China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

Pfizer
Merck Sharp & Dohme LLC
Boundless Bio, Inc.
Sichuan Baili Pharmaceutical Co., Ltd.
MedSIR
ExpreS2ion Biotechnologies
Stemline Therapeutics, Inc.
Genentech, Inc.
Cellectar Biosciences, Inc.
SURGE Therapeutics
Eli Lilly and Company
Celcuity Inc
Arvinas Estrogen Receptor, Inc.
Tolmar Inc.
Jazz Pharmaceuticals
Hoffmann-La Roche
Regor Pharmaceuticals Inc.
AstraZeneca
Eisai Inc.
SCRI Development Innovations, LLC
Beijing Wehand-Bio Pharmaceutical Co., Ltd.
Shandong Suncadia Medicine Co., Ltd.
InventisBio Co., Ltd
Daiichi Sankyo
TransThera Sciences (Nanjing), Inc.
Atridia Pty Ltd.
Novartis Pharmaceuticals
Olema Pharmaceuticals, Inc.
Greenwich LifeSciences, Inc.
Incyclix Bio

1. Key Findings and Analyst Commentary

Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

Key takeaways
Incidence / Prevalence
Diagnosed and Drug-Treated populations
Comorbidities
Other relevant patient segments

4. Market Size and Forecast

Key takeaways
Market drivers and constraints
Drug-class specific trends
Country-specific trends

5. Competitive Landscape

Current therapies
Key takeaways
Dx and Tx journey/algorithm
Key current therapies - profiles and KOL insights
Emerging therapies
Key takeaways
Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
Notable early-phase pipeline